SANGUINE
Unknown
3,000 enrolled
Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma
Phase 1 Unknown
96 enrolled
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma
Phase 2 Unknown
10 enrolled
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
Phase 1/2 Unknown
40 enrolled
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
Phase 1 Unknown
11 enrolled
A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.
Phase NA Unknown
130 enrolled
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
Phase 1/2 Unknown
36 enrolled
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
Phase 1 Unknown
55 enrolled
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
Phase 3 Unknown
360 enrolled
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2 Unknown
104 enrolled
BELIEVE-01
Phase 3 Unknown
150 enrolled
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Phase 1/2 Unknown
330 enrolled
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Phase 1 Unknown
499 enrolled
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
Phase 1/2 Unknown
330 enrolled
A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
Phase 1 Unknown
54 enrolled
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1/2 Unknown
51 enrolled
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
Phase 1 Unknown
12 enrolled
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1 Unknown
54 enrolled
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
Phase 1 Unknown
260 enrolled
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 1 Unknown
75 enrolled
A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas
Phase 1 Unknown
170 enrolled
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
Phase 1 Unknown
10 enrolled
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Phase 1/2 Unknown
20 enrolled
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Phase 2 Unknown
82 enrolled
A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma
Phase 1 Unknown
85 enrolled
Evaluating Different Doses of Orelabrutinib in MCL
Phase 2 Unknown
40 enrolled
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
Phase 2 Unknown
128 enrolled
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
Phase 1 Unknown
50 enrolled
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1 Unknown
18 enrolled
A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors
Phase 1 Unknown
255 enrolled
Pediatric_PK
Phase 1 Unknown
21 enrolled
Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma
Phase 1 Unknown
38 enrolled
Phase 1 First-in-human Study of JS014
Phase 1 Unknown
60 enrolled
HLX301
Phase 1/2 Unknown
30 enrolled
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
Phase 1/2 Unknown
130 enrolled
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
Phase 1 Unknown
90 enrolled
A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)
Phase 1/2 Unknown
120 enrolled
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
Phase 3 Unknown
218 enrolled
ANCHOR2
Phase 1 Unknown
36 enrolled
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
Phase 1/2 Unknown
81 enrolled
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Phase 1/2 Unknown
80 enrolled
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Phase 1/2 Unknown
40 enrolled
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Phase 1/2 Unknown
40 enrolled
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Phase 1/2 Unknown
40 enrolled
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
Phase 1/2 Unknown
40 enrolled
A Study of TQ-B3525 on Tolerance and Pharmacokinetics
Phase 1 Unknown
60 enrolled
The Pilot Study of Medical Device-Neuclare for Patients With Mild Cognitive Disorder and Early Dementia
Phase NA Unknown
20 enrolled
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Phase 1 Unknown
29 enrolled
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma
Phase 1/2 Unknown
92 enrolled
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
Phase 1 Unknown
33 enrolled